Back

Sona Nanotech CEO to present Targeted Hyperthermia Therapy on Sept. 17

Verifying
  • Sona Nanotech said CEO David Regan will present Targeted Hyperthermia Therapy at OTC Markets’ investor forum.
  • Targeted Hyperthermia Therapy triggered immune responses in 8 of 10 biopsied tumors.
  • Sona is preparing a combination study involving patients who previously failed immunotherapy drugs.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.